Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“FDA approves new non-opioid pain drug.
The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (NaV1.8), for the treatment of moderate to severe acute pain. The decision provides a much-needed new treatment option for acute pain management.”
More posts featuring Vivek Subbiah.